Publication | Closed Access

Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women

Second-line TreatmentBreast OncologyPost-menopausal Indian WomenMedicineCancer ManagementPharmacologyGynecologyBreast CancerPharmacotherapyMenopauseCost EffectivenessOncologyRadiation OncologyEndocrine-related CancerWomen's HealthMenopause Hormone Therapy